Literature DB >> 8877542

The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria.

K E Bowker1, M Wootton, H A Holt, D S Reeves, A P MacGowan.   

Abstract

The in-vitro activity of trovafloxacin and nine other antimicrobials was determined for 413 non copy anaerobic clinical isolates. Trovafloxacin was the most active quinolone tested with an MIC90 of 0.5 mg/L against Gram-positive cocci (n = 75); MIC90 of 4 mg/L against Gram-positive bacilli (n = 151); MIC90 of 0.5 mg/L for Gram-negative cocci (n = 12) and MIC90 of 1 mg/L for Gram-negative bacilli (n = 175). Overall the MIC90 of trovafloxacin was 1 mg/L which was equivalent to co-amoxiclav and one dilution higher than that of imipenem. The other seven comparators, including clindamycin and metronidazole, had higher MIC90 values than trovafloxacin. Trovafloxacin is likely to have clinically useful activity against anaerobes from human infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877542     DOI: 10.1093/jac/38.2.271

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Antimicrobial susceptibility of clinically relevant Gram-positive anaerobic cocci collected over a three-year period in the Netherlands.

Authors:  A C M Veloo; G W Welling; J E Degener
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

2.  In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria.

Authors:  A P MacGowan; K E Bowker; M Wootton; H A Holt; D S Reeves
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 3.  Gram-positive anaerobic cocci.

Authors:  D A Murdoch
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

4.  Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.

Authors:  D R Snydman; N V Jacobus; L A McDermott; S E Supran
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.

Authors:  A J Fischman; J W Babich; A A Bonab; N M Alpert; J Vincent; R J Callahan; J A Correia; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.